InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

0
Player Avatar bvdbreaker (< 20) Submitted: 10/8/2009 7:42:32 AM : Outperform Start Price: $14.06 ITMN Score: -47.66

undervalued pipeline, period

Report this Post Reply

Featured Broker Partners


Advertisement